Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors
Alberto F. Sobrero(Ospedale Policlinico San Martino), Paolo Bruzzi(Alleanza Contro il Cancro), Daniel J. Sargent(National Institute of Agricultural Botany), Alessandro Pastorino(Ospedale Policlinico San Martino)
Cited by 31
Related Papers
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
|New England Journal of Medicine|2001|992
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
|Journal of Clinical Oncology|2008|695
Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study
|Journal of Clinical Oncology|2005|541
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
|JNCI Journal of the National Cancer Institute|2011|527